Advertisement

Topics

Alnis BioSciences, Inc Company Profile

16:20 EDT 21st June 2018 | BioPortfolio

Alnis' ultimate goal is to provide a patient with a therapeutic, a NanoGel, that is able to selectively find and treat diseased tissues with no unwanted effects. Additionally, upon release of the chemotherapeutic payload, the nanoparticles are designed to disintegrate into harmless materials that are subsequently cleared from the patient. Alnis seeks to achieve these goals by combining the latest products and concepts in chemical and biological therapeutics and targeted drug delivery together in a nanoparticle as small as a monoclonal antibody. Alnis' therapeutic particles are nanoscopic hydrogels, or NanoGels. These NanoGels are comprised of biologically active molecules covalently attached to a soluble hydrogel core. The outer surface of the NanoGel is coated with ligands that target diseased tissues. Even if currently marketed drugs are used for all of the components, these NanoGel compositions would in themselves be novel, and because our nanoparticles are comprised of bioactive agents already approved by the FDA, our products may reach market faster than and new chemical entity with lower risk of failure in clinical trials

Research proof-of-concept has been achieved by Alnis and its collaborators with anticancer and antibiotic NanoGels, targeting has demonstrated anti-cancer efficacy both in vitro and in vivo, and diagnostic product candidates have phenotypic-specifically enhanced magnetic resonance images of tumors.. We plan to develop our own proprietary nanoparticle therapeutics and demonstrate their efficacy in humans before partnering with larger companiesAlnis' ultimate goal is to provide a patient with a therapeutic, a NanoGel, that is able to selectively find and treat diseased tissues with no unwanted effects. Additionally, upon release of the chemotherapeutic payload, the nanoparticles are designed to disintegrate into harmless materials that are subsequently cleared from the patient. Alnis seeks to achieve these goals by combining the latest products and concepts in chemical and biological therapeutics and targeted drug delivery together in a nanoparticle as small as a monoclonal antibody.

Alnis' therapeutic particles are nanoscopic hydrogels, or NanoGels. These NanoGels are comprised of biologically active molecules covalently attached to a soluble hydrogel core. The outer surface of the NanoGel is coated with ligands that target diseased tissues. Even if currently marketed drugs are used for all of the components, these NanoGel compositions would in themselves be novel, and because our nanoparticles are comprised of bioactive agents already approved by the FDA, our products may reach market faster than and new chemical entity with lower risk of failure in clinical trials

Location

626 Bancroft Way #3B
Berkeley
California
94710
United States of America

Contact

Phone: 510-845-1641
Fax: 510-845-1535
Email: alnis@alnis.com


News Articles [633 Associated News Articles listed on BioPortfolio]

ASC Biosciences, Inc. announces ad dates for first television commercial

About ASC Biosciences, Inc.ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company with a proprietary adult stem cell platform capable Read more...

SOLID BIOSCIENCES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Solid Biosciences Inc. to Contact The Firm

NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Solid Biosciences Inc. ("Solid Biosciences" or th...

Kuros Biosciences Ltd.: Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus

Schlieren (Zürich), Schweiz, 8. Januar 2018 Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus Kuros Biosciences AG (SIX: KURN) gibt die Ausdehnung des exklusiven Lizenzabkommens mit Checkm...

African Women for Biosciences Platform Launched

Women in biosciences remain grossly under represented in leadership and decision-making levels, limiting contribution of scientific research to national development. A new platform - the African Women...

Apricus Biosciences, Inc.: Apricus Biosciences Announces Proposed Public Offering

SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that ...

Apricus Biosciences, Inc.: Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros

Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative me...

Kaskela Law LLC: IMPORTANT SHAREHOLDER DEADLINE ALERT: Solid Biosciences, Inc. - SLDB

RADNOR, PA / ACCESSWIRE / May 23, 2018 / Kaskela Law LLC reminds Solid Biosciences, Inc. (NASDAQ: SLDB) ("Solid Biosciences" or the "Company") investors that a class action complaint has been filed...

SOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF ...

Solid Biosciences investors should visit us at https://www.claimsfiler.com/cases/view-solid-biosciences-inc-securities-litigationor call to speak to our claim center toll-free at (844) 367-9658.   ...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic

The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudom...

Companies [352 Associated Companies listed on BioPortfolio]

Alnis BioSciences, Inc

Alnis' ultimate goal is to provide a patient with a therapeutic, a NanoGel, that is able to selectively find and treat diseased tissues with no unwanted effects. Additionally, upon release of the chem...

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. (formerly Sigma-Tau Pharmaceuticals, Inc.) is a U.S.-based, wholly owned subsidiary of Leadiant Biosciences S.p.A., a research-based pharmaceutical comp...

JeNu Biosciences

JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...

DaVinci Biosciences LLC

DaVinci Biosciences LLC is a privately held company dedicated to advancing therapies that improve the quality of life for individuals suffering from trauma, disease and degenerative disorders. Through...

More Information about "Alnis BioSciences, Inc" on BioPortfolio

We have published hundreds of Alnis BioSciences, Inc news stories on BioPortfolio along with dozens of Alnis BioSciences, Inc Clinical Trials and PubMed Articles about Alnis BioSciences, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alnis BioSciences, Inc Companies in our database. You can also find out about relevant Alnis BioSciences, Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record